Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option Exercise and Stock Sale
SEC Form 4 Filing
Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 27, 2024, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, exercised options to purchase 3,250 shares of common stock at a price of $2.48 per share.
- Simultaneously, Hohl sold 3,250 shares of common stock at a weighted average price of $16.9732, with individual sales prices ranging from $16.60 to $17.58.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Hohl directly owns 0 shares of common stock and 242,620 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider trading activity. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged trading plan mitigates concerns about insider information being used.
Key Dates
| Date | Description |
|---|---|
| 08/02/2022 | One-fourth of the option shares vested. |
| 06/26/2023 | Rule 10b5-1 trading plan adopted by the Reporting Person. |
| 02/27/2024 | Date of option exercise and stock sale. |
| 08/02/2031 | Expiration date of the stock option. |
| 02/29/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.